We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.16%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$1.09B
AUM Growth
+$89.1M
Cap. Flow
-$8.77M
Cap. Flow %
-0.8%
Top 10 Hldgs %
54.62%
Holding
69
New
7
Increased
12
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M
2
INCY icon
Incyte
INCY
+$10.7M
3
PFE icon
Pfizer
PFE
+$10.1M
4
BMY icon
Bristol-Myers Squibb
BMY
+$9.98M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$5.12M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$19.4M
2
PRGO icon
Perrigo
PRGO
+$14.9M
3
AGN
Allergan Inc
AGN
+$9.3M
4
IBB icon
iShares Biotechnology ETF
IBB
+$8.72M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$7.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.61%
2 Financials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NPSP
51
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$2.74M 0.25%
82,900
– –
EPZM
52
DELISTED
Epizyme, Inc
EPZM
$2.18M 0.2%
+70,162
New +$1.65M
BLUE
53
DELISTED
bluebird bio
BLUE
$2.1M 0.19%
4,209
-1,500
-26% -$481K
PTCT icon
54
PTC Therapeutics
PTCT
$6.26B
$2.07M 0.19%
79,150
– –
CLVS
55
DELISTED
Clovis Oncology, Inc.
CLVS
$1.96M 0.18%
47,364
– –
KYTH
56
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$1.88M 0.17%
+49,000
New +$1.71M
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.84M 0.17%
120,400
+73,000
+154% +$1.05M
AMRN
58
Amarin Corp
AMRN
$298M
$1.77M 0.16%
+50,250
New +$1.58M
LITS
59
Lite Strategy Inc
LITS
$33.6M
$1.55M 0.14%
12,196
– –
MGNX icon
60
MacroGenics
MGNX
$240M
$692K 0.06%
31,857
– –
ACHV icon
61
Achieve Life Sciences
ACHV
$647M
$422K 0.04%
51
– –
AEGR
62
DELISTED
Aegerion Pharmaceuticals
AEGR
$1K ﹤0.01%
20
-72,500
-100% -$2.7M
PBYI icon
63
Puma Biotechnology
PBYI
$402M
– –
-185,820
Closed -$19.4M
SUPN icon
64
Supernus Pharmaceuticals
SUPN
$2.65B
– –
-140,800
Closed -$1.26M
PCYC
65
DELISTED
PHARMACYCLICS INC
PCYC
– –
-55,125
Closed -$5.53M
AUXL
66
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-42,165
Closed -$1.15M
QCOR
67
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-117,080
Closed -$7.6M
1 2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Tekla Capital Management held 69 positions worth $1.09B, up 8.9% from $1B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tekla Capital Management's Q2 2014 filing shows 7 new, 12 increased, 10 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 95,957 shares worth $14.1M. The largest sale was Puma Biotechnology, an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q2 2014 buy was Jazz Pharmaceuticals: 95,957 shares worth $14.1M.
  • Tekla Capital Management added most to Incyte in Q2 2014, an estimated $10.7M increase.
  • Tekla Capital Management's biggest Q2 2014 reduction was Perrigo, cutting an estimated $14.9M.
  • Tekla Capital Management fully exited Puma Biotechnology in Q2 2014, selling an estimated $19.4M.
  • Tekla Capital Management's ten largest holdings make up 55% of its $1.09B portfolio in Q2 2014.
  • Tekla Capital Management opened 7 new positions and closed 5 in Q2 2014.
  • Tekla Capital Management's portfolio value rose 8.9% quarter-over-quarter to $1.09B.

Based on Tekla Capital Management's 13F filing for Q2 2014, filed 5 Aug 2014.